The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced a new Community of Practice for Digital Mental Health Technologies, a forum intended to strengthen regulatory understanding and practical support for developers in one of the fastest-growing areas of UK medtech.
The agency set out the plan on its official blog, describing the community as a coordinated effort to help innovators navigate regulatory expectations, improve compliance and move safe, effective digital mental health solutions into clinical use.
A forum for shared learning
The community is to bring together developers, clinicians, researchers, commissioners and regulatory specialists to build a shared understanding of best practice. The MHRA said the need for consistent, practical guidance has grown more urgent as the field expands from therapeutic apps to AI-supported assessment tools.
According to the announcement, the initiative responds to rising demand for clarity on evidence requirements, post-market responsibilities and the evolving regulatory landscape for software-based and AI-enabled mental health tools. The stated objectives are to:
- help developers interpret regulatory requirements and embed compliance earlier in product design;
- identify common challenges facing innovators, particularly small and medium-sized enterprises entering the mental health space;
- share real-world experience from organisations already working through regulatory pathways; and
- strengthen dialogue between industry and regulators so emerging technologies meet safety, performance and evidence expectations.
Survey to set initial priorities
To shape the community's first priorities, the MHRA has opened a survey for digital mental health technology developers and other stakeholders across the medtech ecosystem. It asks about current regulatory challenges, where clearer guidance is needed and how compliance support could be improved.
The agency is seeking broad participation so the community reflects real-world needs rather than top-down assumptions. Developers are encouraged to complete the survey and share it within their organisations; the MHRA frames a strong response as a way to help the community deliver practical support that speeds safe, effective innovation for patients.